An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Trial Profile

An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs NEO-PV 01 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Neon Therapeutics
  • Most Recent Events

    • 19 Dec 2017 Status changed from planning to not yet recruiting.
    • 12 Dec 2017 New trial record
    • 07 Dec 2017 According to a Neon Therapeutics media release, neon therapeutics will collaborate with merck to conduct this phase Ib trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top